Updated: March 5, 2021
As hundreds of people continue to die daily worldwide, German officials will discuss a reported attempt by the Trump administration to secure the rights to any coronavirus vaccine developed by a German pharmaceutical company in crisis meetings on Monday, the Washington Post quoted the country’s interior minister as saying.
The discussions on Monday come amid concerns the Trump administration was trying to monopolize the market, according to Interior Minister Horst Seehofer.
[read_more id="2" more="Read full article" less="Read less"]
Seehofer said he had “heard from several other members of government” that the Trump administration was attempting to secure exclusive rights to any vaccine created by the German biopharmaceutical firm CureVac.
Seehofer said the issue would be discussed in Monday’s regular coronavirus crisis committee meeting.
The gathering also includes representatives of the health ministry and Chancellor Angela Merkel’s office.
The Post quoted Germany’s Welt am Sonntag newspaper as reporting on Sunday that the Trump administration wanted to secure the rights and move research and development to the United States. The vaccine would be developed “only for the USA,” the newspaper added.
According to The Post, “CureVac, based in Tübingen, Germany, pushed back against the report, saying it remains committed to developing a coronavirus vaccine to “help and protect patients worldwide.”
“In a statement, the company said it has contact with many organizations and authorities worldwide and “abstains from commenting on speculations and rejects allegations about offers for acquisition of the company or its technology”, The Post added.